DOXOrubicin Hydrochloride Liposome Injection 50mg/25 mL
Product details
- DOXOrubicin Hydrochloride Liposome Injection 50mg/25 mL
Company announcement
Sun Pharma is recalling DOXOrubicin Hydrochloride Liposome Injection due to the detection of glass particles in some vials during production.
The recall is nationwide and affects one batch of 675 vials.
There have been no reported adverse events related to this issue.
Risk:
If glass particles are administered intravenously, they may pose a risk to patient safety including local irritation or swelling in response to the foreign material. More serious potential risks could include blockage of blood vessels and life-threatening blood clot events.
Impacted states: Nationwide
Products:
- DOXOrubicin Hydrochloride Liposome Injection 50mg/25 mL
Contact
For more information, call 855-745-9357 or email rxrecalls@inmar.com.